Last reviewed: June 24, 2026
Last updated: June 24, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
When choosing a weight loss medication, Zepbound (semaglutide) and Mounjaro (tirzepatide) stand out as FDA-approved options with strong clinical backing. Both belong to the GLP-1 receptor agonist family, yet they work through different mechanisms and produce different results in the body. PlexusDx offers access to both compound versions without insurance requirements, allowing you to explore which aligns best with your health goals.
Understanding the Core Difference: Single vs Dual Action
Zepbound activates only the GLP-1 receptor, triggering appetite suppression and slower stomach emptying. Mounjaro activates both the GLP-1 and GIP receptors simultaneously, creating a dual-hormone effect that some research suggests produces stronger weight reduction. This structural difference means the two medications engage your body's appetite and metabolic pathways in distinct ways.
Clinical trials showed participants using tirzepatide (Mounjaro's active ingredient) achieved greater average weight loss than those on semaglutide alone. In the SURPASS-4 trial, tirzepatide produced up to 22.5% body weight reduction over 68 weeks, compared to semaglutide's typical 15-18% range in comparable studies. The GIP receptor activation appears to enhance insulin sensitivity and energy expenditure beyond what semaglutide achieves alone.
Efficacy and Weight Loss Outcomes: What the Data Shows
Semaglutide users typically see meaningful weight loss within 8-12 weeks, with cumulative results improving through 40+ weeks of therapy. Most people experience 10-20% body weight reduction when combined with lifestyle modifications. This makes Zepbound effective for many individuals, particularly those new to GLP-1 treatment or seeking a gentler entry point.
Tirzepatide demonstrates a steeper weight loss trajectory across clinical populations. The SURPASS trials enrolled over 4,000 participants across multiple studies, consistently showing tirzepatide outperformed semaglutide in head-to-head comparisons. Participants on tirzepatide also reported greater improvements in cardiovascular risk factors and blood sugar control, benefits that extended beyond weight loss alone.
Individual response varies significantly based on genetics, metabolism, and lifestyle factors. PlexusDx's Precision Peptide Genetic Test examines variants in the GLP1R gene (rs6923761), GIPR gene (rs1800437), and metabolic pathways involving FTO and MC4R to predict which mechanism may work best for your genetic profile.
Side Effects and Tolerability: What to Expect
Both medications carry similar gastrointestinal side effects, including nausea, vomiting, and constipation, particularly during dose escalation. Semaglutide side effects tend to occur slightly less frequently than tirzepatide in most users, though individual experiences vary widely. Severe adverse events remain rare in both, with most people adapting after 2-4 weeks on a stable dose.
Tirzepatide users sometimes report stronger nausea during the dose-adjustment phase due to its dual-receptor activation. However, this intensity typically diminishes as the body acclimates. Neither medication causes the liver or kidney problems seen with older weight loss drugs, and both maintain safety profiles across age groups and weight ranges when prescribed appropriately.
Serious side effects like pancreatitis or thyroid tumors remain exceptionally rare with both GLP-1 medications and occur at similar rates. People with personal or family history of medullary thyroid cancer should avoid both options entirely. PlexusDx providers review full medical history before recommending either compound to ensure safety.
Cost, Access, and How PlexusDx Makes Both Affordable
Brand-name Zepbound and Mounjaro typically cost $900-$1,300 per month through traditional pharmacy channels, even with insurance coverage. Many insurance plans classify these as weight-loss drugs and deny coverage entirely, leaving patients to pay out-of-pocket. PlexusDx eliminates these barriers by offering compounded versions through licensed 503A pharmacies at transparent, flat pricing regardless of dose level.
PlexusDx Compounded Semaglutide Injection starts at $149 per month, while PlexusDx Compounded Tirzepatide Injection begins at $249 monthly—a 75-85% reduction compared to brand pricing. Your dose may need to go up. Your price won't. Both medications remain HSA and FSA eligible, providing additional savings opportunities for people with qualifying accounts. PlexusDx serves all 50 states without membership fees, making access truly national.
For those curious about which compound matches their genetics, the Precision Peptide Genetic Test adds just $99 after your first month of treatment. This test analyzes 14 metabolic pathways and 49 peptides, offering science-backed insights into whether your body may respond better to semaglutide's single mechanism or tirzepatide's dual-hormone approach.
Choosing Between Zepbound and Mounjaro: A Practical Framework
Select semaglutide (Zepbound equivalent) if you're new to GLP-1 therapy, prefer a gentler introduction, have mild-to-moderate weight loss goals, or experienced strong nausea with other medications. Semaglutide also suits people with limited budgets, since the $149-per-month entry point is lower. Many patients achieve their target weight on semaglutide alone, avoiding the need for stronger therapy.
Choose tirzepatide (Mounjaro equivalent) if you've had modest results with semaglutide, have significant weight loss targets (25%+ reduction), struggle with insulin resistance or type 2 diabetes, or want the strongest evidence-based option. Tirzepatide's dual action often produces faster visible results and better metabolic improvements. Some patients transition from semaglutide to tirzepatide after 3-6 months when initial results plateau.
PlexusDx providers help you navigate this decision through consultation, medical history review, and optional genetic testing. Starting on one medication doesn't lock you into it—many patients successfully switch between compounds as their needs evolve. The goal remains finding the medication that delivers sustainable weight loss with manageable side effects and cost.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is compounded tirzepatide from PlexusDx the same as brand-name Mounjaro?
PlexusDx Compounded Tirzepatide contains the identical active pharmaceutical ingredient as Mounjaro, manufactured by licensed 503A compounding pharmacies. The difference lies in sourcing, pricing, and branding—compounded versions cost 75-85% less while maintaining the same clinical efficacy and safety profile.
What does the Precision Peptide Genetic Test tell me about Zepbound vs Mounjaro?
The test analyzes your GLP1R and GIPR gene variants (rs6923761 and rs1800437), plus metabolic genes like FTO and MC4R. These insights reveal whether your genetic pathways may respond more strongly to single-receptor (semaglutide) or dual-receptor (tirzepatide) activation, helping PlexusDx providers recommend the best starting medication.
Can I switch from Zepbound to Mounjaro if my results plateau?
Yes, many patients successfully transition from semaglutide to tirzepatide when weight loss slows after 3-6 months. This switch leverages tirzepatide's stronger dual-receptor effect to restart momentum. PlexusDx providers monitor your progress and can facilitate this transition safely with appropriate dose sequencing.
Why is PlexusDx tirzepatide $249/month when brand Mounjaro costs $1,200+?
Brand medications carry manufacturing, marketing, and middleman markups that compounded versions avoid. PlexusDx partners directly with licensed 503A pharmacies, eliminating distributor costs and passing savings to you. Your dose may need to go up. Your price won't—no hidden per-dose increases regardless of escalation.
Are there people who shouldn't use either Zepbound or Mounjaro?
Anyone with personal or family history of medullary thyroid cancer must avoid both GLP-1 medications. Pregnancy, severe kidney disease, or recent pancreatitis also warrant avoidance. PlexusDx providers screen your full medical history before recommending either compound to ensure safety and appropriateness.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Your Zepbound Journey: What Supplements Should I Take While on Zepbound?
Maximizing Your Results: What Can’t You Eat on Wegovy for Better Health